Arcus Biosciences, Inc.

This early-phase study tests a new drug called AB680, combined with immunotherapy (zimberelimab) and two chemotherapy drugs (nab-paclitaxel and gemcitabine), in people with advanced pancreatic cancer that has spread. The main goals are to check safety and find the right dose. Abo…

This phase 3 study tests whether a new combination of two immunotherapy drugs (domvanalimab and zimberelimab) plus chemotherapy works better than the current standard (nivolumab plus chemotherapy) for people with advanced stomach, gastroesophageal junction, or esophageal cancer t…

This phase 2 study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The drugs help the immune system attack cancer cells. Researchers measured how many patients' tumors shrank or stopped growing, and…

This study tested combinations of a new drug called etrumadenant (AB928) with other treatments in 227 people whose colorectal cancer had spread. The goal was to see if these combinations could shrink tumors or slow the cancer's growth. Participants received different drug mixes, …

This study looks at how the drug casdatifan is processed in the body when taken as different tablet strengths and with or without food. It involves 24 healthy adults who will receive single doses under various conditions. The goal is to check if the different forms are equivalent…

This completed Phase 1 study looked at how a single dose of the drug Quemliclustat (with a tiny radioactive tag) is broken down and removed from the body. Eight healthy adult men received the drug by IV and provided blood, urine, and stool samples. The goal was purely to understa…

This study tested how the experimental drug casdatifan interacts with two common medications in 14 healthy adults. Participants received casdatifan alone and then with itraconazole or phenytoin to see how these drugs affect casdatifan levels in the body. The goal was to gather sa…